Adriane Adami
Endocrinology, Diabetes & Metabolism · Panama City, FLNPI 1265273775
Payments from drug & device makers
Across 64 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$194
- Bayer$109
- AstraZeneca$96
- Medtronic$89
- Amgen$71
- Xeris Pharmaceuticals, Inc.$67
- plus $516 from 15 others
What the payments were for
- Food & beverage$1,142100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $194 |
| Bayer | 5 | $109 |
| AstraZeneca(2 entities) | 5 | $96 |
| Medtronic | 3 | $89 |
| Amgen | 4 | $71 |
| Xeris Pharmaceuticals, Inc. | 3 | $67 |
| Novartis | 4 | $57 |
| Sequel Med Tech, LLC | 2 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Lilly USA, LLC | 3 | $50 |
| AbbVie | 3 | $46 |
| Amneal Pharmaceuticals LLC | 2 | $38 |
| Boehringer Ingelheim | 2 | $37 |
| Tandem Diabetes Care, Inc. | 1 | $29 |
| GSK | 1 | $26 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Soleno Therapeutics, Inc. | 1 | $23 |
| Ascendis Pharma Endocrinology Inc | 1 | $21 |
| Dexcom, Inc. | 1 | $20 |
| Abbott | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
How this compares
$1,142 in reported general payments places this provider in the 30th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 69 | $92,433 |
| OzempicSemaglutide | 40 | $47,917 |
| JardianceEmpagliflozin | 20 | $22,414 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $13,442 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $5,493 |
| Novolog FlexpenInsulin Aspart | 15 | $4,442 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $3,258 |
| SynthroidLevothyroxine Sodium | 17 | $1,653 |
| Levothyroxine Sodium | 42 | $513 |
| Atorvastatin Calcium | 11 | $103 |
| Metformin Hcl | 20 | $91 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $50 | $92,43369 claims |
| Novo NordiskOzempic | $194 | $47,91740 claims |
| Boehringer IngelheimJardiance | $37 | $22,41420 claims |
| AbbVieSynthroid | $46 | $1,65317 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $38 | $51342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Panama City
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
- Rodolfo GalindoMiami$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.